Author

Rinse K. Weersma

THE GUT MICROBIOTA SHOWS CHARACTERISTICS OF INFLAMMATION AND CANCER PATHOGENESIS IN GENERAL POPULATION INDIVIDUALS WITH CLONAL HEMATOPOIESIS
THE GUT MICROBIOTA SHOWS CHARACTERISTICS OF INFLAMMATION AND CANCER PATHOGENESIS IN GENERAL POPULATION INDIVIDUALS WITH CLONAL HEMATOPOIESIS

Rinse K. Weersma  et al.

FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18
FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18

Rinse K. Weersma  et al.

DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS
DIETARY INTAKE IS ASSOCIATED WITH FLARE DEVELOPMENT IN IBD PATIENTS

Rinse K. Weersma  et al.

GUT MUCOSA DISSOCIATION PROTOCOLS IMPACTS SINGLE CELL MRNA SEQUENCING RESULTS
GUT MUCOSA DISSOCIATION PROTOCOLS IMPACTS SINGLE CELL MRNA SEQUENCING RESULTS

Rinse K. Weersma  et al.

MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIAC DISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALL INTESTINE
MICRORNAS ARE POTENTIAL EARLY MARKERS OF COELIAC DISEASE AND MAY REGULATE THE COELIAC DISEASE-SPECIFIC TRANSCRIPTIONAL CHANGES IN THE SMALL INTESTINE

Rinse K. Weersma  et al.

USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

LONG-TERM TYPE 1 DIABETES AND ITS COMPLICATIONS ARE ASSOCIATED TO CHANGES IN GUT MICROBIOTA
LONG-TERM TYPE 1 DIABETES AND ITS COMPLICATIONS ARE ASSOCIATED TO CHANGES IN GUT MICROBIOTA

Rinse K. Weersma  et al.

SINGLE CELL RNA SEQUENCING IDENTIFIES DISTINCT INTESTINAL INFLAMMATION PATTERNS BETWEEN PRIMARY SCLEROSING CHOLANGITIS-ASSOCIATED COLITIS AND ULCERATIVE COLITIS
SINGLE CELL RNA SEQUENCING IDENTIFIES DISTINCT INTESTINAL INFLAMMATION PATTERNS BETWEEN PRIMARY SCLEROSING CHOLANGITIS-ASSOCIATED COLITIS AND ULCERATIVE COLITIS

Rinse K. Weersma  et al.

THE GUT MICROBIOME FOLLOW-UP ANALYSIS REVEALS ITS FINGERPRINT POTENTIAL AND CLINICAL RELEVANCE
THE GUT MICROBIOME FOLLOW-UP ANALYSIS REVEALS ITS FINGERPRINT POTENTIAL AND CLINICAL RELEVANCE

Rinse K. Weersma  et al.

INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE
INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE

Rinse K. Weersma  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Rinse K. Weersma  et al.

PROCTOCOLECTOMY WITH PERMANENT ILEOSTOMY IS ASSOCIATED WITH BETTER TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A RETROSPECTIVE COHORT STUDY
PROCTOCOLECTOMY WITH PERMANENT ILEOSTOMY IS ASSOCIATED WITH BETTER TRANSPLANT-FREE SURVIVAL IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A RETROSPECTIVE COHORT STUDY

Rinse K. Weersma  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Rinse K. Weersma  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Rinse K. Weersma  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Rinse K. Weersma  et al.

THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

TNF?-ANTAGONIST USE AND MUCOSAL INFLAMMATION ARE ASSOCIATED WITH INCREASED INTESTINAL EXPRESSION OF SARS-COV-2 HOST PROTEASE TMPRSS2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
TNF?-ANTAGONIST USE AND MUCOSAL INFLAMMATION ARE ASSOCIATED WITH INCREASED INTESTINAL EXPRESSION OF SARS-COV-2 HOST PROTEASE TMPRSS2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Rinse K. Weersma  et al.

GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GUT MICROBIAL CHANGES IN RESPONSE TO VEDOLIZUMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Rinse K. Weersma  et al.

Item 1 - 20 / 39
1
2